OTC Healthcare in Estonia
Euromonitor International's OTC Healthcare in Estonia market report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, packaging innovations, economic/lifestyle influences, distribution or pricing issues. Forecasts illustrate how the market is set to change.
Get immediate access to strategic market analysis when you buy reports online
Tables: 17 | Publication date: Apr 2007
Why buy this report
- Get insight into trends in market performance
- Pinpoint growth sectors and identify factors driving change
- Identify market and brand leaders and understand the competitive environment
Product coverage
Adult mouthcare; Allergy care; Analgesics; Calming and sleeping products; Child-specific OTC healthcare; Cough; cold and allergy (hay fever) remedies; Digestive remedies; Ear care; Emergency contraception; Eye care; Medicated skin care; NRT Smoking cessation aids; OTC obesity; OTC statins; Vitamins and dietary supplements; Wound treatments
Executive summary
OTC healthcare is expanding
In 2005, sales of OTC healthcare achieved EEK392 million, a rise of 7% on the previous year. The fastest growth was achieved by ear care (15%) and medicated skin care (13%).
This market growth was achieved by a multiplicity of advertising and product promotions, growing consumer income and consciousness of OTC products coupled with a lack of time to visit the doctor. People prefer to go to pharmacies to solve health problems by buying the medicines immediately rather than spending time at a surgery waiting to see a doctor.
Two dominant local producers
In Estonia, there are two leading domestic medicinal products manufacturers: Tallinna Farmaatsiatehas AS and Nycomed SEFA AS. There are only seven manufacturers in the country as GMP (Good Manufacturing Practice) requirements are enforced meaning that companies must spend time and money adhering to these. For this reason Grindeks abandoned the production of tablets and ampoules in Tallinna Farmaatsaitehas AS and invested more in Latvia. There are approximately 150 people involved in medicinal products manufacturing in Estonia.
New Medical Products Act in Estonia
The new Medicinal Products Act entered into force on 1 March 2005. The previous act from 1996, amended several times was repealed together with several lower implementing acts. Several new decrees from the Government of the Republic and from the Minister of Social Affairs, based on the new act, were also published in Estonia. The new act regulates manufacture, handling, distribution, marketing, prescribing, advertising and authorisation of medicinal products (both human and veterinary) and gives the rules for supervision and liability.
Table of contents
OTC HEALTHCARE IN ESTONIA : MARKET INSIGHT
1. EXECUTIVE SUMMARY
2. OPERATING ENVIRONMENT
2.1 OTC Registration and Classification
2.2 Vitamins & Dietary Supplements Registration and Classification
2.3 Advertising
2.4 Packaging and Labelling
2.5 Distribution
2.6 De-listing or De-reimbursement
Summary 1 Reimbursement Rates for Pharmaceuticals in Estonia
2.7 Traditional Remedies
2.8 Homeopathy
2.9 Generics
2.10 Consumer Expenditure on Health Goods and Medical Services
Table 1 Consumer Expenditure on Health Goods and Medical Services 2000-2004
Table 2 Consumer Expenditure by Type of Household 2000-2004
2.11 Life Expectancy
Table 3 Life Expectancy at Birth 2000-2005
3. OTC HEALTHCARE SALES
3.1 Market Performance
Table 4 Retail Sales of OTC Healthcare by Sector: Value 2000-2005
Table 5 Retail Sales of OTC Healthcare by Sector: % Value Growth 2000-2005
3.2 Switches
Summary 2 OTC Healthcare Switches 2004-2005
3.3 Competitive Environment
Table 6 OTC Healthcare Company Shares by Retail Value 2001-2005
Table 7 OTC Healthcare Brand Shares by Retail Value 2002-2005
3.4 Leading Company Profile: Nycomed SEFA AS
Summary 3 Nycomed SEFA AS: Operational Indicators 2003-2004
3.5 Leading Company Profile: Tallinna Farmaatsiatehas AS
Table 8 Tallinna Farmaatsiatehas AS: Number of Registered Pharmaceuticals According to Country
Summary 4 Tallinna Farmaatsiatehas AS: Operational Indicators 2005
3.6 New Product Developments
Summary 5 OTC Healthchare: New Product Launches 2004-2005
3.7 Retail Distribution
Table 9 Retail Sales of OTC Healthcare by Distribution Format: % Analysis 2000/2005
Table 10 Retail Sales of OTC Healthcare by Sector and Distribution Format: % Analysis 2005
3.8 Retailer Activity and Private Label Trends
3.9 Forecast Market Performance
Table 11 Forecast Retail Sales of OTC Healthcare by Sector: Value 2005-2010
Table 12 Forecast Retail Sales of OTC Healthcare by Sector: % Value Growth 2005-2010
4. DEFINITIONS